Apellis Pharmaceuticals Announces Conference Call to Discuss Q3 2025 Results

October 16, 2025 — Leads & Copy — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) will host a conference call and webcast on Thursday, October 30, 2025, at 8:30 a.m. ET to discuss its third quarter 2025 financial results.

To access the live call by phone, pre-register here. A live audio webcast of the event and slides can be accessed on the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A webcast replay will be available for 90 days.

Apellis Pharmaceuticals is a biopharmaceutical company focused on complement science to develop therapies for challenging diseases. They have two C3-targeting medicines approved to treat four serious diseases, including the first therapy for geographic atrophy and the first treatment for patients 12 and older with C3G or primary IC-MPGN.

Investor Contact:
Eva Stroynowski
eva.stroynowski@apellis.com
617.938.6229

Source: Apellis Pharmaceuticals, Inc.

×

Welcome!

BiotechReporter.news is a Leads & Copy Publication

Leads & Copy is a Media “news tip” source, providing Industry Reporters story Leads, written as Publishable CP-style Copy.

By Subscribing you will receive Daily Biotech Story Leads via email 10:30 am Mon-Fri.